Weight reduction drugmaker Novo Nordisk will reduce the record costs of Ozempic and Wegovy by as much as 50% starting in 2027, the corporate introduced on Tuesday.
Wegovy presently carries a record worth of $1,349 per thirty days, whereas Ozempic is listed at $1,028 for a one-month provide. Each medication will probably be listed at $675 per thirty days starting on Jan. 1, 2027, “representing reductions of roughly 50% and 35% for Wegovy and Ozempic, respectively,” in response to Novo Nordisk.
The worth reduce will probably be designed to make Ozempic and Wegovy extra reasonably priced for individuals who obtain the diabetes and weight problems medication by means of their medical insurance, Novo Nordisk mentioned.
Some insurance coverage hyperlink protection and out-of-pocket prices to the record worth of medicines. The upcoming worth cuts would be the most useful for “people with high-deductible well being plans or co-insurance profit designs,” mentioned Jamey Millar, government vp of U.S. operations.
Novo Nordisk already introduced Ozempic and Wegovy worth cuts for some individuals final yr, with the medication now costing $349 per thirty days for these paying full worth with out insurance coverage. The medication can even be cheaper for these on Medicare after the corporate reduce a take care of President Trump’s administration.
Tuesday’s announcement got here at some point after the Denmark-based firm launched a research that exposed its deliberate subsequent technology weight reduction drug, CagriSema, couldn’t sustain with Eli Lilly’s Zepbound and Mounjaro in a scientific trial.
